GlassScriptPhysician profile
Jason C Wickens
NPI 1003860313
$1,737.25
in general payments reported to CMS, 2019-2025
19 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $12.19 · 2021: $193 · 2022: $255 · 2023: $411 · 2024: $258 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736 · Education: $73.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.04 |
| Education | $73.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $432.17 | 2019-2022 | |
| Genentech USA, INC. | $296.60 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $204.66 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $137.57 | 2024 | Izervay |
| Regeneron Pharmaceuticals, INC. | $120.90 | 2022-2025 | Eylea, Eylea Hd |
| New World Medical,INC. | $85.86 | 2023 | |
| Alimera Sciences, INC. | $75.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $75.05 | 2022-2024 | Eylea Hd |
| Allergan, INC. | $56.14 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $53.53 | 2023-2024 | Xipere |
| Abbott Laboratories | $42.96 | 2019-2020 | |
| Oculus Surgical INC. | $34.35 | 2021 | |
| Amgen INC. | $26.69 | 2025 | Pavblu |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.79 | 2021 | |
| Biogen, INC. | $20.01 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $19.44 | 2019 | |
| Boston Scientific Corporation | $16.02 | 2025 | General - Pain Management |
| Abbvie INC. | $14.76 | 2023 | Ozurdex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.